Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financi...(we may make. We do not have a policy of ...),Health

SVNT-I

    SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS
    (Unaudited)
    (In thousands, except share data)

                                                        December   December
                                                           31,        31,
                                                          2008       2007
     ASSETS
     Current Assets:
      Cash and cash equivalents                         $76,315     $124,865
      Short-term investments (including
       restricted investments)                            2,282       17,557
      Accounts receivable, net                              822        1,490
      Notes receivable                                        -          644
      Inventories, net                                    1,892        2,636
      Recoverable income taxes                            5,526        8,637
      Prepaid expenses and other current assets           2,782        3,105
         Total current assets                            89,619      158,934
      Deferred income taxes, net                          4,200        3,558
      Property and equipment, net                         1,393        1,599
      Other assets (including restricted cash
       and investments)                                   3,010        3,082
         Total assets                                   $98,222     $167,173
     LIABILITIES AND STOCKHOLDERS' EQUITY
     Current Liabilities:
      Accounts payable                                   $5,888       $3,758
      Deferred revenues                                     451        1,298
      Other current liabilities                          18,650       14,128
         Total current liabilities          
'/>"/>
SOURCE  Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related medicine news :

1. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
4. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
5. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
6. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
7. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
8. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
11. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results